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Fig 1. Bullous fixed drug eruption: Erythematous circular
superficial erosion with desquamative scale overlying left
nasal ala.
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Localized bullous fixed drug eruption
following yellow fever vaccine
To the Editor: Yellow fever is a potentially fatal,
mosquito-borne disease endemic to areas of South
America and Africa. The yellow fever vaccine is
recommended to those traveling to high-risk areas
and is considered one of the safest and most effective
vaccines ever developed. The vaccine is a live atten-
uated version of the 17D strain grown in egg embryos
and imparts durable immunity for 10 years. Reported
dermatologic side effects of the vaccine include mild
injection site reactions, urticaria, and anaphylaxis.1
We report a case of an injection site reaction
followed by a localized bullous fixed drug eruption
after the administration of the yellow fever vaccine.
Hours after receiving the vaccine, a painful edematous
plaque developed at the injection site in a healthy 56-
year-old woman. Four days later, she reported devel-
opment of large, asymptomatic bullae localized to her
nose. The lesions increased in size and eventually
ruptured with minimal crust. She presented to our
clinic 10 days after receiving the vaccine. The patient
had no known allergies to medications, eggs, or
vaccines, and denied a history of herpes or changes
to her medication regimen. She reported no insect
bites, trauma, or burns to the area. On exam, therewas
Open access under CC BY-NC-ND license.a 1.2-cm erythematous, circular, superficial erosion
with desquamative scale overlying the left nasal ala
with scant hemorrhagic and serous crust (Fig 1).
Superficial erosions were also appreciated on the
columella. An erythematous patch surrounded the
injection site on the upper right arm. Biopsy, culture,
and direct immunofluorescence were deferred given
thebenign exam.Because the lesionswerehealing, no
specific treatment was indicated. The eruption cleared
2 days later without scarring or dyspigmentation.
The history and clinical findings were consistent
with the yellow fever vaccine producing a mild
injection site reaction and subsequent bullous fixed
drug eruption on the left nasal ala. Herpes simplex,
herpes zoster, and arthropod bites, while considered
with findings of bullae, were unlikely here given the
history, time course, and lack of symptoms. The
possibility of bullous impetigo was also weighed but
the characteristic turbid vesicular fluid and yellow
crusting were not present and the patient did not
possess risk factors such as sick contacts. Autoimmune
blistering diseases were not favored due to the
localized and self-limited nature of the lesions.
Although rare, various bullous eruptions have
been described following vaccination. Bullous pem-
phigoid has been reported to occur most commonly
after receipt of the influenza vaccine, as well as after
receipt of the diphtheria-tetanus-pertussis vaccine.2
Influenza and human papillomavirus vaccinations
have triggered the appearance of linear IgA bullous
disease.3,4 Generalized bullous fixed drug eruption
has developed after receipt of the flu vaccine.5
Unlike our patient’s limited and self-resolved erup-
tion, these eruptions were widespread, generally
requiring systemic therapy and an autoimmune
J AM ACAD DERMATOL
MAY 2014
e114 Lettersworkup. This localized, yet distant, bullous fixed
drug reaction to the injection site in our patient likely
represents a benign, idiosyncratic reaction to the
vaccine that requires no treatment.
Eric Y. Sako, BS, Ashley Rubin, MD, and Lorraine
C. Young, MD
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